Mirati Therapeutics is to appeal against the European Medicines Agency’s recommendation that pan-EU marketing approval should be refused for Krazati (adagrasib), the company’s US-approved treatment for KRASG12C -mutated advanced non-small cell lung cancer (NSCLC).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?